Four Cases with FUS/CHOP Fusion Gene Products Positive Myxoid Liposarcoma Responding Effectively to Trabectedin Monotherapy.

Onco Targets Ther · 2024 · PMC11577931 · PMID 39569033

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

When limited to the patients with myxoid round cell liposarcoma, the response rate was elevated to 21% (3/14), and the progression-free survival was 7.3 months, showing a favorable trend.

also in 714 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.